News
Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
1d
MyChesCo on MSNMadrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...
Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...
Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...
Explore more
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
Zacks.com on MSN12d
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpDuring the quarter, the company generated total revenues of $137.3 million, entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom), ...
Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...
Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results